VGXI

The Woodlands, United States Founded: 1997 • Age: 29 yrs
Contract developer and manufacturer of plasmids
Annual revenue - Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About VGXI

VGXI is a company based in The Woodlands (United States) founded in 1997. VGXI operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Seer, Alector and Scailyte, among others.

  • Headquarter The Woodlands, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of VGXI

Headcount 50-200
Employee Profiles 18
Employee Profiles
People
Jeff Whitmore
Chief Commercial Officer
People
Alyssa Osborne
Process Development Technician
People
Young K. Park
President & CEO
People
Christy Franco
Senior Director Of Commercial Operations

Unlock access to complete

Funding Insights of VGXI

Investors in VGXI

VGXI has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CEPI.

All
Venture Fund
Investor Description Founded Year Domain Location
Healthcare investments are targeted by this private equity firm.
Locked Locked Locked
Premium access

Investor details for VGXI

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by VGXI

Investments
Premium access

Investment portfolio details for VGXI

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - VGXI

Premium access

Detailed financials for VGXI

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Vgxi Comparisons

VGXI Primary company
Description
Contract developer and manufacturer of plasmids
Location
The Woodlands, United States
Founded Year
1997
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for VGXI

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of VGXI

VGXI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Seer, Alector and Scailyte, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Solutions for biomarker discovery and diagnostic testing are provided.
Locked Locked Locked
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
Locked Locked Locked
Proteomics platform developed for early cancer and neurological disease detection.
Locked Locked Locked
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
Locked Locked Locked
Single-cell data is analyzed via AI for biomarker discovery.
Locked Locked Locked
NeoPhore is focused on cancer neoantigen evolution therapies.
Premium access

Detailed competitors of VGXI

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Vgxi

Premium access

Complete news archive for VGXI

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about VGXI

VGXI was founded in 1997 and raised its 1st funding round 23 years after it was founded.

VGXI is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.

Young K Park is the current CEO of VGXI.

VGXI was established in 1997 as a contract manufacturing organization in the biotechnology sector, based in The Woodlands, United States. Services encompass cGMP plasmid DNA production for clinical and commercial applications, highly documented plasmids for viral and toxicological studies, and high-purity preparations for preclinical research. As a subsidiary of GeneOne Life Science, operations support DNA vaccine and gene therapy development.

VGXI's top competitors include Alector, Maze Therapeutics and Metabolon.

VGXI has 1 investor. Key investors include CEPI.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available